Cutiss
cutiss.swiss
Actively hiring
Science & Engineering
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$62.7M
1 round on record
Latest round
$62.7M
Series C · Sep 2025 · 12 mo ago
Team
11-50
employees, estimated range
The money's age
Due for its next round
12 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
2017
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series C | Sep 2025 | $62.7M | — | YahooFinance |
Registers and programsofficial lists and records that name the company
| Legal entity | CUTISS AG | its site |
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Nuance Pharma are an innovation focused biopharmaceutical company, with both late-stage clinical pipeline and commercial stage asset…
Developing Breakthrough PET Imaging and Therapeutic Radiopharmaceuticals Learn More About Us Established in 2019, Innervate…
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing…
Simulate your spacecraft from DAY ZERO. De-risk, verify and launch — with no late-stage, costly redesigns during integration.
Scioto Biosciences is a preclinical stage biotech company dedicated to innovative research and discovery in the field of microbiome…
The Next Generation in. OncoSenX is a late stage pre-clinical cancer company headquartered in Seattle, Washington. OncoSenX targets solid…
News
Rai 1's Noos: inside CUTISS and the making of denovoSkin
Italian national broadcaster Rai 1 visited CUTISS for a feature on denovoSkin as part of Noos - L'avventura della conoscenza, the popular science programme hosted by Alberto Angela. The reportage takes viewers inside CUTISS' GMP manufacturing facility in
Read more
Report
Dr. Achim von Leoprechting elected Chairman of CUTISS Board of Directors
Former Tecan CEO joins CUTISS as the company strengthens its Board for the next phase of growth. Switzerland, 23 June 2026 - CUTISS, a late-stage clinical company at the forefront of tissue therapeutics and regenerative medicine, has announced the electio
Read more
Report
Interview by Ringier: Daniela Marino on skin, innovation and the future of burn care
CEO and co-founder Daniela Marino is featured in the summer 2026 edition of Interview by Ringier, the Swiss magazine dedicated to in-depth conversations with personalities from business, science, culture, politics and sport. In the four-page interview, ti
Read more
Report
CUTISS granted U.S. patent for automated skin graft production methods
CUTISS has been granted a new patent in the United States for automated methods and systems for producing skin grafts. The patent (U.S. Patent No. 12,599,401 B2), titled "Methods and systems for producing skin grafts", covers automated methods and systems
Read more
Report
Watson: focus on CUTISS' bio-engineered skin technology for severe burns
Swiss online news platform Watson visited CUTISS for an in-depth report on denovoSkin and the potential of bio-engineered skin to support patients with severe burn injuries. The video and online report take readers inside CUTISS' GMP manufacturing facilit
Read more
Report
New publication reports 1-year phase II results for denovoSkin in reconstructive surgery
A new peer-reviewed publication reports 1-year results from a prospective, randomized, intra-patient controlled, multicenter phase II clinical trial evaluating denovoSkin in reconstructive surgery in patients of all ages. The study evaluated denovoSkin ag
Read more
Report
CUTISS granted U.S. patent for disposable hydrogel compression system in skin tissue engineering
CUTISS has been granted a new patent in the United States for a disposable system and method used in the preparation of compressed hydrogels for tissue engineering applications.The patent (U.S. Patent No. 12,564,662 B2), titled "Disposable system and meth
Read more
Report
New publication reports U.S. compassionate use of denovoSkin in pediatric reconstructive surgery
A new peer-reviewed report in the Journal of Burn Care & Research describes the compassionate use of denovoSkin in a pediatric patient with extensive burn injuries treated at Massachusetts General Hospital (Boston, USA).The publication details reconstruct
Read more
Report
NZZ explores advances in skin replacement for severe burn patients
Swiss newspaper Neue Zürcher Zeitung (NZZ) has featured CUTISS and denovoSkin in an in-depth report on the challenges of treating patients with severe burns and the development of laboratory-engineered skin. Published in NZZ's Forschung und Technik sectio
Read more
Report
denovoSkin positive safety & efficacy 1-year readout in Phase 2 trial for adolescent and adult burn patients
CUTISS is pleased to share that the 1-year results of the Phase IIb clinical trial evaluating denovoSkin in adolescent and adult burn patients have been published in eClinicalMedicine, part of The Lancet Discovery Science.The prospective, randomized, cont
Read more
Report
Show more news
Financials
Total raised
$62.7M
Latest round
Series C
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series C | 2025 | $62.7M | Details |